Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion

被引:4
|
作者
Christopher Valerio [1 ]
Eleni Theocharidou [2 ]
Andrew Davenport [3 ]
Banwari Agarwal [1 ]
机构
[1] Intensive Care Unit, Royal Free Hospital, Royal Free Hampstead NHS Trust, University College London
[2] the Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, Royal Free Hampstead NHS Trust and Institute of Liver and Digestive Health, University College London
[3] UCL Centre for Nephrology, Royal Free Hospital
关键词
Human serum albumin; Human albumin solution; Critical illness; Cirrhosis; Resuscitation fluid; Large-volume paracentesis; Hepatorenal syndrome; Spontaneous bacterial peritonitis;
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
To provide an overview of the properties of human serum albumin(HSA), and to review the evidence for the use of human albumin solution(HAS) in critical illness, sepsis and cirrhosis. A MEDLINE search was performed using the terms "human albumin", "critical illness", "sepsis" and "cirrhosis". The references of retrieved articles were reviewed manually. Studies published between 1980 and 2014 were selected based on quality criteria. Data extraction was performed by all authors. HSA is the main plasma protein contributing greatly to its oncotic pressure. HSA demonstrates important binding properties for endogenous and exogenous toxins, drugs and drug metabolites that account for its anti-oxidant and anti-inflammatory properties. In disease states, hypoalbuminaemia is secondary to decreased HSA production, increased loss or transcapillary leakage into the interstitial space. HSA function can be also altered in disease with reduced albumin binding capacity and increased production of modified isoforms. HAS has been used as volume expander in critical illness, but received criticism due to cost and concerns regarding safety. More recent studies confirmed the safety of HAS, but failed to show any survival benefit compared to the cheaper crystalloid fluids, therefore limiting its use. On the contrary, in cirrhosis there is robust data to support the efficacy of HAS for the prevention of circulatory dysfunction post-large volume paracentesis and in the context of spontaneous bacterial peritonitis, and for the treatment of hepato-renal syndrome and hypervolaemic hyponatraemia. It is likely that not only the oncotic properties of HAS are beneficial in cirrhosis, but also its functional properties, as HAS replaces the dysfunctional HSA. The role of HAS as the resuscitation fluid of choice in critically ill patients with cirrhosis, beyond the established indications for HAS use, should be addressed in future studies.
引用
收藏
页码:345 / 354
页数:10
相关论文
共 50 条
  • [41] Prognostic value of lactate/albumin ratio in patients with acute-on-chronic liver failure
    Golcuk, Yalcin
    Golcuk, Burcu Kaymak
    ANNALS OF HEPATOLOGY, 2023, 28 (06)
  • [42] ALBUMIN BILIRUBIN SCORE FOR PREDICTING MORTALITY IN SUDANESE PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE
    Barri, Esraa
    Kheir, Omer
    Barakat, Salma
    GUT, 2021, 70 : A107 - A107
  • [43] Albumin dialysis in patients with acute exacerbation of chronic liver failure in an intensive care unit
    Moragues Ribes, Concepcion
    Cases Viedma, Enrique
    Ruano Marco, Miguel
    MEDICINA CLINICA, 2006, 127 (17): : 641 - 644
  • [44] Acute-on-chronic liver failure: a new syndrome in cirrhosis
    Moreau, Richard
    CLINICAL AND MOLECULAR HEPATOLOGY, 2016, 22 (01) : 1 - 6
  • [45] Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis
    Arroyo, Vicente
    Moreau, Richard
    JOURNAL OF HEPATOLOGY, 2017, 66 (02) : 451 - 453
  • [46] Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute on chronic liver failure (ACLF)
    Mezzano, G.
    Cardenas, A.
    Aguilar, F.
    Pavesi, M.
    Sole, C.
    Sola, E.
    Napoleone, L.
    Graupera, I.
    Juanola, A.
    Carol, M.
    De Prada, G.
    Fabrellas, N.
    Martinez, J.
    Saliba, F.
    Welzel, T.
    Arroyo, V.
    Gines, P.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S244 - S244
  • [47] Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation
    Zaccherini, Giacomo
    Baldassarre, Maurizio
    Bartoletti, Michele
    Berardi, Sonia
    Tame, Mariarosa
    Napoli, Lucia
    Siniscalchi, Antonio
    Fabbri, Angela
    Marconi, Lorenzo
    Antognoli, Agnese
    Iannone, Giulia
    Domenicali, Marco
    Viale, Pierluigi
    Trevisani, Franco
    Bernardi, Mauro
    Caraceni, Paolo
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E698 - E698
  • [48] Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation
    Zaccherini, Giacomo
    Baldassarre, Maurizio
    Bartoletti, Michele
    Tufoni, Manuel
    Berardi, Sonia
    Tame, Mariarosa
    Napoli, Lucia
    Siniscalchi, Antonio
    Fabbri, Angela
    Marconi, Lorenzo
    Antognoli, Agnese
    Iannone, Giulia
    Domenicali, Marco
    Viale, Pierluigi
    Trevisani, Franco
    Bernardi, Mauro
    Caraceni, Paolo
    JHEP REPORTS, 2019, 1 (04) : 270 - 277
  • [49] Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure
    Bernsmeier, Christine
    Cavazza, Anna
    Fatourou, Evangelia M.
    Theocharidou, Eleni
    Akintimehin, Abisoye
    Baumgartner, Benjamin
    Dhar, Ameet
    Auzinger, Georg
    Thursz, Mark
    Bernal, William
    Wendon, Julia A.
    Karvellas, Constantine J.
    Antoniades, Charalambos G.
    McPhail, Mark J. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (05) : 855 - 865
  • [50] Acute-on-chronic liver failure in Egypt: an underestimated complication of liver cirrhosis
    Medhat, Mohammed A.
    Gushken, Fernanda
    Khaled, Tasneem
    Hassan, Elham
    Abd El-Rehim, Abeer
    Kamel, Sherif
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E458 - E463